GeneDx CEO Katherine Stueland likes the potential of newborn testing, but she says her Stamford, Connecticut, company is ...

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of GeneDx ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

GAITHERSBURG, Md. - GeneDx (NASDAQ: WGS), a genomic insights company valued at $1.64 billion, has launched its services on Aura, Epic's specialty diagnostics suite, to facilitate advanced genetic ...

Grizzly Research has shorted GeneDx, a genetic testing company, accusing them of widespread fraud. GeneDx specializes in advanced genomic testing, with a focus on rare and ultra-rare genetic disorders ...

GeneDX Holdings reports Q4 earnings on February 18th. Find out why WGS stock is a strong play in the booming genetics testing ...

GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone ...

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for ...

On Wednesday, GeneDx (NASDAQ:WGS) shares maintained their ground following a reiteration of a Hold rating and a $75.00 price target by Jefferies analysts. According to InvestingPro data, analyst ...